Cochrane Review: Anticholinergic drugs and dementia: time for transparency in the face of uncertainty

Zusammenfassung

Anticholinergic drugs and dementia: time for transparency in the face of uncertainty | Cochrane Library Skip to Content Cookies Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in About Cookies . I accept Basic Search Title Abstract Keyword Record Title Abstract Author Keyword All Tex

Kerninformationen

فارسی Français हिन्दी Hrvatski Bahasa Indonesia 日本語 한국어 Magyar Bahasa Malaysia Nederlands Polski Português Русский Română தமிழ் ภาษาไทย 繁體中文 简体中文 Website language Select your preferred language for the Cochrane Library website. English Español Cancel Save Sign In Related Reviews Protocols Cochrane D...

pathways, are commonly used in clinical practice for the management of many conditions affecting older adults. For some such drugs, anticholinergic effects are the mechanism of therapeutic action (e.g. oxybutynin, used to treat some forms of urinary incontinence). For others, anticholinergic effects...

r Derrick Dunlop). In the case of anticholinergic drugs, some adverse effects are short‐term and obvious (e.g. dry mouth, constipation) whereas others may be insidious and irreversible – one such concern related to long‐term ACB is a possible contribution to cognitive decline and dementia. Over rece...

Fragen zu diesem Thema?

ClariMed durchsucht alle Leitlinien mit KI und liefert quellenbasierte Antworten in Sekunden.

Jetzt auf ClariMed suchen